| Literature DB >> 16820184 |
Danher Wang1, Michael Hevey, Laure Y Juompan, Charles M Trubey, Nicholas U Raja, Stephen B Deitz, Jan Woraratanadharm, Min Luo, Hong Yu, Benjamin M Swain, Kevin M Moore, John Y Dong.
Abstract
The Marburg virus (MARV), an African filovirus closely related to the Ebola virus, causes a deadly hemorrhagic fever in humans, with up to 90% mortality. Currently, treatment of disease is only supportive, and no vaccines are available to prevent spread of MARV infections. In order to address this need, we have developed and characterized a novel recombinant vaccine that utilizes a single complex adenovirus-vectored vaccine (cAdVax) to overexpress a MARV glycoprotein (GP) fusion protein derived from the Musoke and Ci67 strains of MARV. Vaccination with the cAdVaxM(fus) vaccine led to efficient production of MARV-specific antibodies in both mice and guinea pigs. Significantly, guinea pigs vaccinated with at least 5 x 10(7) pfu of cAdVaxM(fus) vaccine were 100% protected against lethal challenges by the Musoke, Ci67 and Ravn strains of MARV, making it a vaccine with trivalent protective efficacy. Therefore, the cAdVaxM(fus) vaccine serves as a promising vaccine candidate to prevent and contain multi-strain infections by MARV.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16820184 DOI： 10.1016/j.virol.2006.05.033
Source DB: PubMed Journal: Virology ISSN： 0042-6822 Impact factor: 3.616